Periodic Reporting for period 1 - GNU200 (Innovative Solution in Microbiome Modulation to Benefit Infant Healthy growth)
Reporting period: 2018-01-01 to 2018-04-30
GNUbiotics has developed GNU 200, a disruptive prebiotic ingredient based on by-products from the farming industry that successfully mimics the human milk oligosaccharides (HMOs) profile of breast milk. By implementing GNU 200, infant formula manufacturers will be able to offer products that promote infants’ microbiome, resulting in multiple health benefits.
GNU 200 has reached TRL 6 and is protected by a patent. We have produced 50 kg of compound at pilot scale and demonstrated its performance in preclinical studies. The last development steps will be achieved through GNU 200 project by scaling up the technology to industrial capabilities and fulfilling the regulatory and market requirements to guarantee its successful market deployment.
2. We have conducted an analysis on the infant formula and functional ingredients’ market and validated our commercialisation and IP strategy. Additionally, we have updated our dissemination plan.
3. We have further defined our funding needs and forecasted GNU 200 financial projections up to 2024.
The outcome of this Feasibility Study is the decision to continue with the project.
Being sourced from a farming industry by-product, GNU 200 will also help to prevent the economic and environmental impacts of animal waste while creating an additional source of income for the pork industry, therefore promoting a circular economy in the agro-food sector.